Aurora Therapeutics Launches to Realize Potential of Personalized Gene Editing for Millions of Patients with Rare Diseases




Aurora Therapeutics Launches to Realize Potential of Personalized Gene Editing for Millions of Patients with Rare Diseases

– Leveraging modular gene editors and new regulatory pathways, Aurora will develop and commercialize therapies that can be rapidly tailored to many rare variants –

– Founded by CRISPR pioneers Jennifer Doudna and Fyodor Urnov to scale up impact of gene editing therapies –

– Company incubated by Menlo Ventures with an experienced management team led by CEO Edward M. Kaye –

BOSTON–(BUSINESS WIRE)–Aurora Therapeutics today announced its official launch to transform personalized gene editing from a one-patient breakthrough into a scalable model capable of bringing therapies to millions of patients with rare diseases. The company launches with a $16 million seed financing from Menlo Ventures to create the first platform for treating rare genetic mutations that have historically been impossible to address at scale.

Aurora was founded by Jennifer Doudna, Ph.D., CRISPR co-inventor and Nobel Laureate, and Fyodor Urnov, Ph.D., a leader in translating genome-editing science into human therapeutics. Their vision builds on more than a decade of progress in CRISPR technology, including clinical validation and advances in rapid sequencing and mutation identification, opening the door to personalized therapies that correct rare, disease-causing mutations unique to each patient.

Aurora is now realizing this next frontier of genetic medicine through a repeatable, systematic approach. Following advances in guide design and AI-generated editors combined with innovations in regulatory and CMC strategies, the company aims to shift personalized gene editing from isolated breakthroughs to a platform capable of benefiting patients with rare mutations at the population scale.

“Aurora’s launch signals a turning point for personalized gene editing. We now have the science, tools and regulatory tailwinds needed to move from isolated success stories to a sustainable way of developing many therapies in parallel,” said Edward M. Kaye, M.D., Chief Executive Officer of Aurora Therapeutics. “Our team’s deep experience in rare disease drug development positions us to advance this vision with rigor and urgency.”

“Since its discovery, CRISPR has offered the promise of treating the root causes of genetic disease, but we lacked a scalable way to bring those therapies to patients with rare mutations,” said Aurora co-founder Jennifer Doudna, Ph.D. “By innovating in both clinical development and approval pathways, Aurora is showing the true promise of gene editing for patients who were previously out of reach.”

A key component of Aurora’s model is its use of emerging regulatory frameworks that support grouping multiple mutations within a disease into unified development paths. This umbrella approach is designed to make personalized therapies economically and operationally viable, addressing a longstanding gap in rare-disease drug development. Aurora is uniquely positioned to execute this model by pairing deep gene-editing expertise and hands-on clinical experience with purpose-built clinical, manufacturing, and quality systems designed for rapid, parallel development of mutation-specific therapies.

“Aurora is opening a new frontier in genetic medicine,” said Johnny Hu, Ph.D., Principal at Menlo Ventures. “We believe that the pairing of recent advances in gene editing and AI with a scalable development and regulatory strategy will dramatically expand the number of people who can benefit from gene editing. Menlo is excited to support the team in increasing access to these life-changing therapies.”

Aurora’s initial program focuses on phenylketonuria (PKU), a metabolic disorder caused by a wide range of mutations in the PAH gene that lead to toxic elevations of phenylalanine in the blood. Without early treatment and careful monitoring, PKU can lead to impaired brain development in children and adolescents. Even when early and strict disease control enables near-normal IQ, elevated phenylalanine levels continue to negatively affect cognitive functions — such as executive function, memory, and social skills — throughout life. For this reason, PKU requires lifelong management.

“Every week, PKU specialist physicians like me care for individuals with PKU who are unable to consistently maintain safe phenylalanine levels,” said Chet Whitley, Ph.D., M.D., Medical Director of the PKU Clinic and Professor of Pediatric Genetics & Metabolism at the University of Minnesota. “Gene editing has the potential to offer a definitive and durable treatment for PKU and other genetic diseases, and Aurora’s model provides a promising path to extend these therapies to far more patients — not just a limited subset.”

PKU’s high unmet need and well-characterized disease biology align closely with the U.S. Food and Drug Administration’s recently announced plausible mechanism pathway. Supported by published preclinical proof-of-concept data and encouraging regulatory feedback, Aurora is designing therapeutics intended to address multiple PKU-causing mutations from the outset, with plans to expand this approach to additional mutations over time.

Leadership Team and Board of Directors

Aurora has assembled a leadership team and Board of Directors comprising veteran biotechnology experts with deep experience in rare diseases and genetic medicine.

Leadership Team

• Edward M. Kaye, M.D., Chief Executive Officer
• Thomas Wechsler, Ph.D., Chief Scientific Officer
• David Litvak, MBA, Head of CMC and Technical Operations
• Morgan Maeder, Ph.D., Head of Research

Board of Directors

• Johnny Hu, Ph.D., Principal at Menlo Ventures (Chair)
• Greg Yap, Partner at Menlo Ventures
• Edward M. Kaye, M.D., Chief Executive Officer
• Fyodor Urnov, Ph.D., Professor of Molecular Therapeutics at University of California, Berkeley; Scientific Director of the Innovative Genomics Institute

Founders

• Jennifer Doudna, Ph.D., Li Ka Shing Chancellor’s Chair and a Professor in the Departments of Chemistry and of Molecular and Cell Biology at the University of California, Berkeley; Howard Hughes Medical Institute investigator; President and Chair of the Board of the Innovative Genomics Institute
• Fyodor Urnov, Ph.D., Professor of Molecular Therapeutics at University of California, Berkeley; Scientific Director of the Innovative Genomics Institute

About Aurora Therapeutics

Aurora Therapeutics is reinventing how personalized gene-editing medicines are developed and approved for patients with rare diseases. The company combines state-of-the-art CRISPR engineering with umbrella regulatory pathways and modular CMC frameworks that allow many mutation-specific therapies to move forward in parallel. Aurora’s approach addresses the fundamental economic and operational barriers that have historically prevented treatments for rare mutations, enabling CRISPR therapies to reach patients at population scale. For more information, visit http://auroratherapeutics.com.

About Menlo Ventures

Menlo Ventures is a leading early-stage venture capital firm investing in digital health and novel life science companies. Our portfolio includes more than 85 public companies and over 170 exits through mergers and acquisitions. Currently managing more than $7 billion in assets, we invest at the intersection of bio and tech, across consumer, enterprise, and healthcare, with a differentiated approach in core thesis areas including therapeutic platforms, transformative technologies, digital health, and healthcare SaaS. Our portfolio companies include Benchling, Chai Discovery, Delfi, Eleos Health, Function Health, Gilead, H1, PillPack, Recursion, and Xaira. We strive to have a positive impact on everything we do, and we believe innovations at the intersection of tech and bio will drive major improvements in the quality of our health and the cost of healthcare. When we’re in, we’re ALL IN.

Contacts

Media Contact
Lisa Raffensperger

Ten Bridge Communications

lisa@tenbridgecommunications.com

Insulet to Announce Fourth Quarter and Full Year 2025 Financial Results on February 18, 2026 




Insulet to Announce Fourth Quarter and Full Year 2025 Financial Results on February 18, 2026 

ACTON, Mass.–(BUSINESS WIRE)–Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod^® brand of products, today announced it will report financial results for the fourth quarter and full year of 2025 on February 18, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time).

The link to the live call will be available on the Investor Relations section of the Company’s website at investors.insulet.com, “Events and Presentations,” and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203-2109 for international callers; the passcode is 5904836.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit: insulet.com and omnipod.com.

©2026 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved.

Contacts

Investor Relations: 

Clare Trachtman 

Vice President, Investor Relations 

ir@insulet.com 

Media: 

Angela Geryak Wiczek 

Senior Director, Corporate Communications 

pr@insulet.com  

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis




MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis

• MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD)
• STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies

GHENT, Belgium–(BUSINESS WIRE)–#Parkinson–MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD).

About the STARFISH-UC Phase 2b Trial

The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of six well-characterized commensal strains. The study (NCT07296315) will enroll approximately 204 patients with mild-to-moderate ulcerative colitis (UC) inadequately controlled by 5 aminosalicylic acid (5 ASA) with or without low-dose steroids, the current standard of care. The trial will run across Europe and the U.S., featuring a 12-week placebo-controlled induction phase with two dosing regimens, followed by a 40-week open-label extension. Enrollment is expected to begin mid-2026.

Promising Clinical Results to Date

A previous Phase 2a trial with MH002 in mild-to-moderate UC suggested excellent safety and encouraging efficacy upon 8 weeks of treatment, indicative of mucosal healing and anti-inflammatory effects, recovery of the gut microbiome and induction of clinical remission. No safety signals or adverse reactions were observed. Additionally, MH002 showed positive results in an open-label study for acute pouchitis, underscoring its broad therapeutic potential.

Executive Commentary

“Receiving IND clearance from the FDA is a testament to MH002’s robust clinical foundation and its potential to transform the lives of those living with UC,” stated Sam Possemiers, CEO of MRM Health. “The upcoming STARFISH-UC study is a critical next step in our mission to deliver a convenient, immune system-sparing, one-pill solution for IBD patients. We are excited to further validate MH002’s benefits and advance it as a frontrunner among innovative UC treatments.”

Innovative Technology and Manufacturing

MH002 is engineered using MRM Health’s proprietary CORAL® platform, which enables the design and scalable cGMP manufacturing of complete microbial consortia as a single drug substance. This approach offers regulatory and patient compliance advantages, supporting the development of cost-effective, high-quality therapeutics for chronic inflammatory conditions.

***

About MRM Health

MRM Health is a clinical-stage biotech developing innovative microbiome-based Live Biotherapeutic Products for chronic inflammatory diseases with high unmet need. Its CORAL® platform enables the design and manufacture of disease-focused microbial consortia with enhanced efficacy and scalability. In addition to advancing lead program MH002 into pivotal clinical development in ulcerative colitis and the orphan disease indication, pouchitis, MRM Health has ongoing preclinical programs in other inflammatory diseases and immune-oncology. In September 2025, MRM Health successfully closed a 55M€ Series B Round led by Biocodex, with strong support of ATHOS, BNP Paribas Fortis Private Equity and existing investors SFPIM, AvH, OMX Europe VF, QBic and VIB.

For more information, please follow us on LinkedIn or visit the website at www.mrmhealth.com.

MRM Health will attend the JP Morgan Week and Biotech Showcase 2026 in San Francisco (January 12-15). If you are interested in learning more about MRM Health programs, please schedule a meeting using the Biotech Showcase partneringONE portal or the Company’s direct contact info@mrmhealth.com.

Contacts

Corporate
MRM Health NV

Dr. Sam Possemiers – CEO

info@mrmhealth.com

Media relations

International & DACH
MC Services AG

Anne Hennecke

Phone: +49.151.125.557.59

anne.hennecke@mc-services.eu

Media relations

BeNeLux/France
Backstage Communication

Gunther De Backer

Phone: +32.475.903.909

gunther@backstagecom.be

Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments




Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments

Voluntary agreement will allow millions of Americans to purchase medicines at significantly discounted rates

Agreement provides Johnson & Johnson pharmaceutical products an exemption from U.S. tariffs

Company announces two new additional manufacturing facilities to be built in North Carolina and Pennsylvania; continues to deliver on $55 billion U.S. investment

NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most comprehensive innovation powerhouse, today announced a voluntary agreement with the Trump Administration to improve access to medicines and lower costs for millions of American patients. The joint agreement meets the requests laid out by President Trump to the industry and provides the Company’s pharmaceutical products an exemption from tariffs¹.

“Today’s agreement shows that when the public and private sectors work together towards shared goals, we can deliver real results for patients and the U.S. economy,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “I’m proud that Johnson & Johnson is answering President Trump’s call to lower drug prices for everyday Americans while maintaining our role in improving and saving lives and ensuring that the United States continues to lead the world in healthcare innovation.”

Improving Access and Lowering Costs for U.S. Patients

Johnson & Johnson is working with the Trump Administration to improve access to medicines and lower costs for millions of American patients. The Company is:

• Participating in TrumpRx.gov, a direct to patient platform, which will allow millions of American patients to purchase medicines from Johnson & Johnson at significantly discounted rates.
• Enabling American patients to access medicines at comparable prices to other developed countries.
• Providing Medicaid program access at comparable prices to other developed countries.
• Continuing to support the Administration’s efforts to ensure better recognition of the value of health care across developed markets globally.

Delivering On Our $55B U.S. Investment

Johnson & Johnson also continues to deliver on our previously announced $55 billion investment to support U.S. manufacturing, research and development, and technology investments by early 2029. In just the last 10 months, the Company has initiated billions of dollars in investment in U.S. manufacturing, which will support the Company’s goal of manufacturing the vast majority of its advanced medicines in the U.S. to meet the needs of U.S. patients.

Today, as part of the $55 billion investment, the Company is announcing two new U.S. manufacturing facilities, including a next generation cell therapy manufacturing site in Pennsylvania and a state-of-the-art drug product manufacturing facility in North Carolina.

Additionally, construction is progressing on our $2 billion state-of-the-art biologics manufacturing facility in Wilson, North Carolina, which the Company broke ground on last year. That project will create approximately 5,000 skilled manufacturing and construction jobs in the state. Johnson & Johnson is already ramping up the hiring of advanced manufacturing employees to work at the facility.

In September, the Company also secured a new 160,000+ square foot dedicated biopharmaceutical manufacturing site in Holly Springs, North Carolina. The $2 billion commitment over the next 10 years will create approximately 120 new jobs in North Carolina.

Johnson & Johnson expects to announce additional U.S. investments later this year.

About Johnson & Johnson:

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more at www.jnj.com.

Cautions Concerning Forward-Looking Statements

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory actions; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

¹ Specific terms of the agreement remain confidential.

Contacts

Media contact:
media-relations@its.jnj.com

Investor contact:

investor-relations@its.jnj.com

FineHeart Secures €83 Million to Support Its Growth and Establish Itself as a Future European Leader in Active Implantable Medical Devices (AIMDs)




FineHeart Secures €83 Million to Support Its Growth and Establish Itself as a Future European Leader in Active Implantable Medical Devices (AIMDs)

• €35 million Series C funding to accelerate the clinical and industrial development of FlowMaker^®
• €48 million in grants from the IPCEI Tech4Cure program to structure the European Active Implantable Medical Devices (AIMD) sector

BORDEAUX, France–(BUSINESS WIRE)–FineHeart, a clinical-stage medical technology company specializing in the development of innovative solutions for cardiology, announced today the completion of a €35 million first closing of its Series C financing round. This funding is a key lever for activating European public funding, IPCEI Tech4Cure¹, and for establishing its role as a European Active Implantable Medical Devices (AIMDs) leader.

In total, FineHeart has secured €83 million in financing combining private capital and non-dilutive European public funding to accelerate the industrialization and clinical development of FlowMaker^® and establish itself as a future European AIMD leader.

Arnaud Mascarell, CEO and co-founder of FineHeart, said: “We are delighted to welcome new investors at this first closing. I would like to extend my special thanks to Groupe Pasteur Mutualité and the European Innovation Council (EIC) for their key contributions, as well as to our long-standing shareholders, led by FH Founders, for their unwavering support. Together with the IPCEI, this funding strengthens our ambition to build disruptive, IP-protected technologies that enable more predictive, personalized, preventive, and participatory medicine—while advancing Europe’s industrial competitiveness and healthcare sovereignty.”

A first €35 million closing, paving the way for the remainder of the Series C round.

This first €35 million closing brings together new investors, including Groupe Pasteur Mutualité and Groupe Etchart, alongside significant participation from the European Innovation Council (EIC)’s EIB fund. Existing investors—FH Founders (the founders’ holding company bringing together primarily international private investors from healthcare and entrepreneurship), Lurra, IRDI, Groupe Doliam and NACO—renew their confidence and support this next FlowMaker development phase.

“Groupe Pasteur Mutualité acts for health by combining prevention, solidarity, and support for innovation. By supporting FineHeart, we fund a technology that can transform the treatment of severe heart failure, driven by the same ambition: to advance health for everyone,” declared Thierry Lorente, Managing Director of Groupe Pasteur Mutualité.

€48 million in grants under the IPCEI Tech4Cure¹: FineHeart, European leader in AIMDs

In parallel, FineHeart is to benefit from €48 million in grants from the IPCEI Tech4Cure program, disbursed in several tranches, in its role as the lead partner in the project to structure the European AIMD sector. The work will focus on key technological challenges inherent to AIMDs, including:

• Miniaturization of power supply systems,
• Drastic reduction of energy requirements,
• Long-term reliability and durability of implantable systems.

These innovations form a technological pillar of FlowMaker^® developed by FineHeart

The advisors involved in this transaction:

• Legal advisors : Olivier Mourain & cabinet La Tour International – La Tour International
• Auditors : Aeccelis & Forvis Mazars Secteurs – Forvis Mazars
• Helinnov conseil

About FlowMaker^®

FlowMaker^® is the world’s first fully implantable cardiac output accelerator designed to treat advanced heart failure. Fully intraventricular, it provides physiological support synchronized with the natural heart contractions. It respects natural blood flow and does not require aortic bypass. By operating in synergy with native cardiac contractions, the FlowMaker^® consumes little energy and does not require any percutaneous connection to external batteries. It is recharged via a transcutaneous energy transfer (TET) system, thereby reducing any risk of infection and significantly improving patients’ quality of life. The device is implanted through a minimally invasive procedure on a beating heart, with an average duration of 90 minutes. This procedure is widely practiced by cardiac surgeons and limits any physiological changes.

About FineHeart – www.fineheart.com

FineHeart is a clinical-stage medical device company based in Bordeaux and Tours. Its innovative product, FlowMaker^®, could treat 200,000 patients with advanced heart failure every year. FineHeart is initially targeting the 50,000 most severe patients eligible for cardiac assistance and not treated by current LVADs. This first potential market is estimated at over 5 billion euros.

FineHeart was founded by CEO Arnaud Mascarell and a team of internationally renowned cardiac surgeons and electro-physiologists, including Dr. Stéphane Garrigue, CSO and inventor of the concept, and Dr. Philippe Ritter, co-inventor of cardiac resynchronization therapy (CRT). The company holds an international portfolio of 160 patents in 27 different families.

Financed by a consortium of public and private investors, including the founders’ holding company, FH Founders, as well as Doliam, Etchart Group, and investment funds Groupe Pasteur Mutualité, Lurra, Aquiti Gestion, Galia Gestion, Broadview Ventures, IRDI Capital Investment, M Capital, UI Investment & Verve Capital. FineHeart is supported by the European Union (EIC), Bpifrance and the Nouvelle-Aquitaine and Centre-Val de Loire regions.

¹Important Project of Common European Interest (‘IPCEI’) Tech4Cure.

Contacts

Europe
Media Relations

Annie-Florence Loyer

afloyer@newcap.fr
+33 (6) 88 20 35

FineHeart Communications
James Palmer

j.palmer@orpheonfinance.com
+33 (0) 7 60 92 77 72

Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026




Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

Planned Leadership Transition Positions Company for Growth

Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025

BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the “Board”) has appointed Everett Cunningham as the Company’s next President and Chief Executive Officer and a member of the Board, effective January 19, 2026.

Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham’s start date, Dr. Toloue will remain available to the Company in an advisory capacity to support continuity and help ensure a smooth leadership transition. Contemporaneous with Mr. Cunningham’s appointment, Bill Donnelly, Executive Chair of the Board, will transition to his prior role as non-executive Chair of the Board.

Since June 2024, Mr. Cunningham has served as Chief Commercial Officer of Illumina, a global leader in DNA sequencing and array-based technologies, where he was responsible for the company’s global commercial strategy and execution. During his tenure, Mr. Cunningham helped implement a redesigned commercial operating model to improve customer engagement and accelerate the commercialization of Illumina’s sequencing- and array-based solutions for genetic and genomic analysis. Previously, Mr. Cunningham served as Chief Commercial Officer at Exact Sciences, where he led marketing, sales, and customer service across the company’s portfolio of cancer screening and precision oncology diagnostics. Earlier in his career, he held senior leadership roles at Quest Diagnostics, GE Healthcare and Pfizer.

“We are excited to welcome Everett to Quanterix,” said Bill Donnelly, Executive Chair of the Board. “Throughout his career, Everett has demonstrated his ability to accelerate growth at both research tools and diagnostics companies, build high-performing commercial organizations and lead transformational change at scale. His deep understanding of our customers and markets and his track record of operational execution makes him exceptionally well suited to lead Quanterix in its next phase of growth.”

Mr. Cunningham’s appointment follows a comprehensive search process, with the assistance of a leading executive search firm, as part of the Board’s long-term succession planning efforts.

Mr. Donnelly continued, “On behalf of the Board, I want to thank Masoud for his many contributions to Quanterix. Under his leadership, the Company significantly expanded its assay menu, entered adjacent markets, and built its Diagnostics business from the ground up, advancing the translation of its technology into clinical applications. These initiatives, together with the transformative acquisition of Akoya Biosciences, have positioned Quanterix for broader scientific impact, deeper clinical relevance and enhanced long-term value creation. To that end, we are pleased to share that we expect to exceed our guidance for revenue and cash for the full year 2025. We appreciate Masoud’s continued leadership during this transition and wish him every success in his next chapter.”

Mr. Cunningham commented, “I am thrilled to join Quanterix as Chief Executive Officer at such an exciting time for the Company. With its differentiated technology platform, expanding portfolio and talented team, Quanterix is uniquely positioned to lead the next wave of innovation in advanced disease detection and therapeutic development. I look forward to working closely with the Board and my colleagues to advance the Company’s mission to improve health outcomes worldwide and deliver meaningful value for shareholders, patients, partners and other stakeholders.”

About Everett Cunningham

Everett Cunningham, age 58, has served as Chief Commercial Officer of Illumina, Inc. (NASDAQ: ILMN), a global leader in sequencing- and array-based solutions for genetic and genomic analysis since June 2024. Prior to Illumina, he was Chief Commercial Officer of Exact Sciences Corporation (NASDAQ: EXAS), a leader in cancer screening and precision oncology diagnostics, from 2021 to 2024, overseeing global marketing, sales, and customer service functions.

Before joining Exact Sciences, Mr. Cunningham served as President & Chief Executive Officer of GE Healthcare’s U.S. & Canada region from 2019 to 2021. Earlier, he served as Senior Vice President, Commercial at Quest Diagnostics Inc. (NYSE: DGX), where he was responsible for global sales, marketing, and commercial operations from 2012 to 2019. And prior to that, from 1991 to 2012, Mr. Cunningham held a range of senior leadership positions at Pfizer Inc. (NYSE: PFE), including Regional President, Established Products for Asia Pacific, Senior Director of Worldwide Learning and Development, Senior Director of Business Operations, Vice President Sales for U.S. Pharmaceuticals, and Vice President of Global Corporate Human Resources.

Mr. Cunningham currently serves on the boards of Arvinas, Inc. (NASDAQ: ARVN) and Visby Medical. At Arvinas, he is a member of the Compensation and Audit committees.

Mr. Cunningham holds a bachelor’s degree in economics from Northwestern University.

Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

In connection with his appointment, Mr. Cunningham will receive long-term equity incentive awards consisting of (i) restricted stock units (RSUs) covering 1,070,000 shares of Company common stock, subject to time-based vesting (the “Time-Based RSUs”) and (ii) RSUs covering 813,750 shares of Company common stock, subject to performance-based vesting (the “Performance-Based RSUs”).

The Time-Based RSUs vest in four equal annual installments on each of the first four anniversaries of Mr. Cunningham’s start date. One-fifth of the Performance-Based RSUs will vest on the later of (i) the date that the volume weighted average price of the Company’s common stock on the Nasdaq Global Market (“VWAP”) equals or exceeds $10 per share for 30 consecutive days prior to the second anniversary of Mr. Cunningham’s start date and (ii) the first anniversary of his start date, two-fifths will vest on the later of (i) the date that such VWAP equals or exceeds $15 per share for 30 consecutive days prior to the third anniversary of Mr. Cunningham’s start date and (ii) the second anniversary of his start date, and the remaining two-fifths will vest on the later of (i) the date that such VWAP equals or exceeds $20 per share for 30 consecutive days prior to the fourth anniversary of Mr. Cunningham’s start date and (ii) the third anniversary of his start date.

The equity awards were granted under the Company’s 2025 Inducement Plan as an inducement material to Mr. Cunningham’s joining Quanterix in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by the Company’s Board of Directors.

About Quanterix

Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With approximately 6,000 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company®, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,396 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics. Learn more at www.quanterix.com.

Cautionary Statement Regarding Forward-Looking Statements

The financial results mentioned above are preliminary, unaudited results and may be subject to change as a result of the completion of Quanterix’s year-end financial reporting and auditing processes.

Statements included in this press release that are not historical in nature or do not relate to current facts are intended to be, and are hereby identified as, forward-looking statements for purposes of the safe harbor provided by Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among other things, statements about Quanterix’s future business outlook, operations, strategy and financial performance, including statements related to our expectations regarding our financial results for the year ended December 31, 2025, about the development and commercialization of our products, and about the benefits we may realize from the acquisition of Akoya Biosciences Inc. Words and phrases such as “may,” “approximately,” “continue,” “should,” “expects,” “projects,” “anticipates,” “is likely,” “look ahead,” “look forward,” “believes,” “will,” “intends,” “estimates,” “strategy,” “plan,” “could,” “potential,” “possible” and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are subject to certain risks and uncertainties that are difficult to predict with regard to, among other things, timing, extent, likelihood and degree of occurrence, which could cause actual results to differ materially from anticipated results. Such risks and uncertainties include, among others, the following possibilities with respect to Quanterix’s future business, operations, strategy and financial performance: risks related to the impact of recent U.S. government policies, including reductions in federal research funding and increased tariffs; risks that we may not realize the expected benefits of our cost reduction actions; risks associated with the anticipated timing for launch of, and features of, Quanterix’s next-generation instrument, Simoa One; risks that Quanterix may fail to realize the anticipated benefits and synergies of its recent acquisitions of Emission, Inc. and Akoya Biosciences Inc.; risk that integrating Quanterix’s business with that of Akoya could be more difficult, costly or time-consuming than expected; Quanterix risks that Quanterix’s estimates regarding expenses, future revenues, capital requirements, and needs for additional financing could be incorrect; risks related to the restatement of Quanterix’s consolidated financial statements, including risks of increased costs and the increased possibility of legal proceedings and regulatory inquiries, sanctions, or investigation; risks related to Quanterix’s ability to maintain effective internal control over financial reporting and disclosure controls and procedures, including its ability to remediate existing material weaknesses in its internal control over financial reporting and the timing of any such remediation; risks related to defects or other quality issues in Quanterix’s products that could lead to unforeseen costs, product recalls, adverse regulatory actions, negative publicity and litigation; risks related to Quanterix’s ability to retain and expand its customer base and achieve sufficient market acceptance of its products; and other factors that may affect future results of Quanterix. Additional factors that could cause results to differ materially from those described above can be found in the periodic reports filed by Quanterix with the SEC, including the “Risk Factors” sections contained therein, which are available on the SEC’s website at www.sec.gov.

All forward-looking statements, expressed or implied, included in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to herein. If one or more events related to these or other risks or uncertainties materialize, or if Quanterix’s underlying assumptions prove to be incorrect, actual results may differ materially from what Quanterix anticipates. Quanterix cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made and are based on information available at that time. Quanterix does not assume any obligation to update or otherwise revise any forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements were made or to reflect the occurrence of unanticipated events except as required by federal securities laws.

Contacts

Investor Contact:
Joshua Young

(508) 846-3327

ir@quanterix.com

GenNx360 Capital Partners Portfolio Company Nutra-Med Packaging Appoints Hany Salama as Chief Executive Officer




GenNx360 Capital Partners Portfolio Company Nutra-Med Packaging Appoints Hany Salama as Chief Executive Officer

NEW YORK–(BUSINESS WIRE)–GenNx360 Capital Partners (“GenNx360”), a New York City-based private equity firm investing in middle-market industrial and business services companies, today announced the appointment of Hany Salama as Chief Executive Officer of its portfolio company, Nutra-Med Packaging (“Nutra-Med” or the “Company”), one of the leading contract development and manufacturing organizations serving the health, wellness, and pharmaceutical sectors. Mr. Salama succeeds Kunal Gupta, effective January 12, 2026.

Mr. Salama brings more than twenty years of global leadership experience across healthcare, biopharma, consumer health, and life sciences. He has held senior operational and commercial roles at some of the world’s most respected organizations, including Johnson & Johnson, Merck, Roche, and BASF. At Johnson & Johnson, he led end-to-end supply chain and manufacturing operations for major consumer brands across complex, highly regulated environments. Most recently, as Senior Vice President and General Manager at McKesson, Mr. Salama oversaw biopharma services, private-label strategy, commercialization, and specialty distribution, driving growth and operational transformation across large-scale, mission-critical platforms.

“Hany’s leadership experience at the intersection of regulated manufacturing, operational excellence, and commercial scale makes him exceptionally well suited to lead Nutra-Med into its next chapter,” said Marie Ffolkes, Managing Partner of GenNx360 Capital Partners. “As Nutra-Med continues to expand its capabilities and deepen customer partnerships, we are confident that Hany’s disciplined approach and strategic perspective will help accelerate growth and strengthen the Company’s market position.”

As Chief Executive Officer, Mr. Salama will focus on advancing Nutra-Med’s core manufacturing capabilities, expanding its service offerings, and scaling the platform to meet growing customer demand. He will work closely with the Company’s experienced leadership team to enhance quality systems, increase capacity, and further differentiate Nutra-Med as a trusted partner to customers across the health, wellness, and pharmaceutical markets.

“We are delighted to welcome Hany to Nutra-Med,” said Kunal Gupta, outgoing Chief Executive Officer. “I am incredibly proud of what our team has built over the past four years and believe Hany is the right leader to guide the Company through its next phase of growth. His experience, leadership style, and vision will be invaluable as Nutra-Med continues to evolve and pursue its significant market opportunity.” Mr. Gupta will transition into the role of President, where he will continue to support Nutra-Med’s long-term success.

“I am honored to join Nutra-Med at such a pivotal moment in the Company’s evolution,” said Mr. Salama. “I look forward to working with the talented Nutra-Med team to build on the Company’s strong foundation, continue delivering high-quality packaging solutions, and create lasting value for our customers and partners.”

About Nutra-Med

Nutra-Med is a Whippany, New Jersey-based company focused on contract packaging for the Pharmaceutical, Health & Wellness and Medical Devices industries. Nutra-Med’s primary service capabilities include bottling, blistering, kitting, and secondary packaging for domestic and global customers. For more information on Nutra-Med, please visit www.nutra-med.com.

About GenNx360 Capital Partners

GenNx360 Capital Partners is a private equity firm focused on acquiring middle market industrial and business services companies. GenNx360 invests in companies with proven and sustainable business models in expanding industries, with the objective of implementing value-enhancing operational improvements to accelerate growth, deliver efficiencies and generate strong financial returns. Target sectors include infrastructure & utility services, commercial & facility services, testing/environmental equipment/services, automation & industrial technology, industrial distribution/supply chain, packaging products/equipment services, food ingredients and equipment/services. GenNx360 was founded in 2006 and is headquartered in New York City. https://www.gennx360.com/

Contacts

Media Contact:
Edward Lopez

Profile Advisors

P: 646-818-9018

E: Elopez@profileadvisors.com

Abbelight Announces Successful Series B Investment led by AVANT BIO to Accelerate Imaging Innovation and Scale Adoption Across a Broader Customer Base




Abbelight Announces Successful Series B Investment led by AVANT BIO to Accelerate Imaging Innovation and Scale Adoption Across a Broader Customer Base

PARIS–(BUSINESS WIRE)–Abbelight, a global leader and a pioneer in super-resolution microscopy end-to-end solutions, today announced a successful Series B financing round led by AVANT BIO, a growth equity firm focused on enabling technologies shaping tomorrow’s therapeutics.

“With a decade of experience in the Life Science Research market, Abbelight has been transforming the way scientists see, quantify, and interpret all kinds of complex intracellular mechanisms. It’s now time to tailor our cutting-edge imaging toolbox to also address new key verticals, such as single cell phenotyping and mechanisms of action validation for drug discovery”, says Nicolas Bourg CTO and co-founder.

“Big things happen at the nanoscale – and Abbelight enables researchers to visualize precise sub-cellular structures like never before”, said Daniella Kranjac, Founding General Partner at AVANT BIO. “Their breakthroughs in super-resolution microscopy and sample-to-insight workflows embody the kind of enabling technologies that accelerate discovery and drive innovation across life sciences”.

“This is an exciting moment for Abbelight. The funding accelerates our commercial expansion and allows us to continue delivering best-in-class support to our 100+ installed base”, said Jean-Baptiste Marie, CEO and co-founder. “AVANT BIO’s support will be key to driving innovation and adoption across the broader bioindustry, including biopharma, biotech, and CROs”.

About Abbelight

Founded in 2016, Abbelight is a fast-growing company specializing in the development of microscopy and nanoscopy (SMLM) solutions. Its portfolio incorporates state-of-the-art chemistry, optics and data analysis enabling researchers at public research institutes and biotech companies to observe and understand complex biological mechanisms and interactions at nanoscale. Today, Abbelight employs around 60 people, all driven by the desire to provide innovative imaging solutions and to support its customers around the world. www.abbelight.com

About AVANT BIO

AVANT BIO is a growth equity firm focused on the enabling technologies which shape how tomorrow’s therapeutics are discovered, developed, and manufactured. With an investment focus engineered to accelerate new growth and innovation at various stages of company development, AVANT BIO is committed to amplifying value and unlocking the full potential of therapeutic enabling technologies, TechBio, and HealthTech. For further information, including opportunities to partner, visit www.avant.bio. Follow AVANT BIO on LinkedIn for the latest news and industry insights.

Contacts

Media:

Jean-Baptiste Marie, CEO

jbmarie@abbelight.com

Media:

Rich Ferraro

rich@avant.bio

Anaergia Appoints Sasha Rollings-Scattergood as Chief Technology Officer




Anaergia Appoints Sasha Rollings-Scattergood as Chief Technology Officer

Mr. Rollings-Scattergood will lead Anaergia’s end-to-end technology strategy, including R&D, product management, and the commercialization of proprietary systems

CARLSBAD, California & BURLINGTON, Ontario–(BUSINESS WIRE)–$ANRG #ANRG—Anaergia Inc. (TSX: ANRG) (OTCQX: ANRGF), a pioneering technology company and global leader in converting waste into renewable fuel, clean water, and fertilizer, appointed Sasha Rollings-Scattergood as Chief Technology Officer, effective January 1, 2026.

Mr. Rollings-Scattergood joined Anaergia in 2012 and progressed through increasingly senior leadership roles, most recently serving as Vice President Technology and Research and Development, while advancing the company’s proprietary technology platforms across global markets.

As Chief Technology Officer, Mr. Rollings-Scattergood will lead Anaergia’s product companies and centralized research and development organization, including stewardship of the company’s global intellectual property portfolio, with responsibility for advancing technologies into repeatable, commercially reliable platforms deployed across Anaergia’s global operations. In his new role, he will also lead Anaergia’s global technology profit and loss function and play an expanded role in shaping the company’s corporate direction and strategy, ensuring technology priorities align with Anaergia’s long-term growth and global expansion. Concurrently, he will continue to lead Anaergia’s end-to-end technology strategy, guiding research and development, product management, and the commercialization of proprietary systems across regions and markets.

“Sasha continues to play a vital role in building Anaergia’s technology leadership,” said Assaf Onn, Chief Executive Officer of Anaergia. “He successfully transforms innovation into systems that perform at commercial scale. His appointment strengthens our execution capabilities and reflects the critical role technology plays in Anaergia’s industry leadership.”

Under Mr. Rollings-Scattergood’s leadership, Anaergia has advanced core technology platforms, scaled proprietary processes from pilot to commercial deployment, and strengthened the integration between technology development and project delivery.

“Technology sits at the centre of Anaergia’s mission,” said Mr. Rollings-Scattergood. “I am proud of the teams we have built, and together we are advancing both breakthrough and continuously improving technologies that perform reliably at commercial scale, deliver measurable environmental benefits, and create durable, long-term value for our customers.”

An environmental engineer by training, Mr. Rollings-Scattergood holds a Bachelor of Science and a Master of Applied Science in Environmental Engineering from the University of Guelph. He is a licensed Professional Engineer in Ontario and has held senior technical and leadership roles with Anaergia in North America, Europe, and Asia. His work has supported the development and commercialization of several of Anaergia’s flagship systems, including OREX^® and other high-solids anaerobic digestion and nutrient recovery technologies.

Mr. Rollings-Scattergood has received industry recognition for his contributions to the clean energy sector, including being named to Forbes Magazine’s 30 Under 30: Energy list.

About Anaergia

Anaergia is a pioneering technology company in the RNG sector, with over 300 patents dedicated to converting organic waste into sustainable solutions such as RNG, fertilizer, and water. It is committed to addressing a significant source of greenhouse gas (GHG) emissions through cost-effective processes. Our proprietary technologies, combined with our engineering expertise and vast experience in facility design, construction, and operation, position Anaergia as a leader in the RNG industry. With a proven track record of delivering hundreds of innovative projects over the past decade, we are well-equipped to tackle today’s critical resource recovery challenges through diverse project delivery methods. As one of the few companies worldwide offering an integrated portfolio of end-to-end solutions, we effectively combine solid waste processing, wastewater treatment, organics recovery, high-efficiency anaerobic digestion, and biomethane production. Additionally, we operate RNG facilities owned by us, by third parties, or through joint ventures. This comprehensive approach not only reduces environmental impact but also significantly lowers costs associated with waste and wastewater treatment while mitigating GHG emissions.

For further information please see: www.anaergia.com

Contacts

For media and/or investor relations please contact: IR@Anaergia.com

EpiBiologics Closes $107M Series B to Advance Pipeline of Novel Bispecific Antibodies to Selectively Degrade Extracellular Protein Targets in Oncology and Immunology




EpiBiologics Closes $107M Series B to Advance Pipeline of Novel Bispecific Antibodies to Selectively Degrade Extracellular Protein Targets in Oncology and Immunology

Proceeds advance multiple programs, including EPI-326 into first-in-human clinical trial in early 2026 for EGFR-driven lung cancer and head and neck cancer

SAN MATEO, Calif.–(BUSINESS WIRE)–EpiBiologics, a leader in tissue-selective extracellular protein degradation, today announced the completion of a $107 million Series B financing co-led by GV (Google Ventures) and Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc (JJDC).

Novartis Venture Fund (NVF), Aulis Capital, Avego BioScience Capital, and Samsara BioCapital joined JJDC as new investors. In addition to GV, existing investors Polaris Partners, Digitalis Ventures, Taiho Ventures, Vivo Capital, Codon Capital, and Mission BioCapital participated in the round.

“We’re delighted to work with this distinguished group of investors as we enter the next stage of EpiBiologics’ growth. This financing allows us to advance our pipeline of novel bispecific antibodies to selectively degrade disease-driving membrane and soluble targets in oncology and immunology,” said Ann Lee-Karlon, Ph.D., Chief Executive Officer of EpiBiologics. “Our lead program, EPI-326, is moving rapidly to the clinic as a highly differentiated therapeutic to address substantial unmet needs for patients with EGFR-driven cancers.”

EPI-326 is a tissue-selective bispecific antibody that degrades all oncogenic forms of EGFR, is mutation-agnostic, and overcomes limitations of existing EGFR therapies by localizing degradation to the tumor while sparing normal healthy tissue. In preclinical studies, EPI-326 drives strong and durable efficacy with favorable safety and pharmacokinetics, enabling both monotherapy and combination approaches for multiple cancer types.

EpiBiologics plans to initiate a first-in-human clinical trial of EPI-326 in early 2026 for non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC). The company continues to build key capabilities as it moves towards the clinic and appointed two new executives in 2025, Eric Humke, M.D. Ph.D., Chief Medical Officer, and Aaron Mishel, Chief Financial Officer, who both have deep biopharma leadership expertise.

Concurrent with Series B financing, the company welcomes new Board members: Anika Gupta Vatsa, Ph.D. (GV), Laura Brass, Ph.D. (NVF), Gaurav Aggarwal, M.D. (Vivo), and a representative from JJDC. Nisa Leung (Aulis), Eric Pham, Ph.D. (Avego), and Mitchell Mutz, Ph.D. (Samsara) will join as Board observers.

“As an early investor, I’ve been impressed by EpiBiologics’ rapid scientific and operational progress as they’ve built the EpiTAC platform and portfolio in oncology, immunology, and beyond,” said David Schenkein, M.D., General Partner at GV. “Anika and I are excited to co-lead this financing as the company translates this innovation into transformative medicines for patients.”

About EpiBiologics

EpiBiologics is advancing a next-generation protein degradation pipeline and platform that targets extracellular membrane and soluble proteins. EpiBiologics was founded on pioneering work from scientific founder Dr. Jim Wells of the University of California, San Francisco (UCSF). The Company’s proprietary EpiTAC platform is a modular bispecific antibody system that enables targeted degradation of disease-driving extracellular proteins in a tissue-specific manner. Headquartered in the San Francisco Bay Area, EpiBiologics is backed by leading healthcare investors and aims to develop first-in-class and best-in-class targeted therapies across multiple therapeutic areas, including oncology and immunology. For more information, please visit epibiologics.com and follow us on LinkedIn.

Contacts

Media Contact
Lisa Raffensperger

Ten Bridge Communications

lisa@tenbridgecommunications.com